Pulmonx Corporation - Common Stock (LUNG)

Gross margins above 75% and a narrowing path to cash flow breakeven give the turnaround real financial teeth.

Revenue returned to growth while losses narrowed significantly on cost discipline.

Pulmonx (NASDAQ:LUNG) reported third-quarter revenue growth and a narrower loss as the company cited progress in rebuilding its U.S. sales organization, tightening expenses and advancing clinical programs intended to expand its market. Total worldwide revenue for the quarter ended Sept. 30 was $22.

Pulmonx (NASDAQ:LUNG) is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat. French, who

Net loss narrowed to $10.1 million as cost cuts offset China suspension.

Pulmonx (NASDAQ:LUNG) reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China. Revenue for the quarter

Pulmonx (LUNG) Q1 2026 Earnings Transcript

Pulmonx (LUNG) Q4 2025 Earnings Call Transcript

In today's session, these stocks are experiencing unusual volume.

Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.